The results of this pilot study show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation presently on the market.
MIST-B04 is formulated using a new drug delivery platform named Trizero, which was developed internally by Mistral’s scientists and for which a patent application was filed in June 2007.
Bertrand Bolduc, president & CEO of Mistral Pharma, said: “The results show that our brand new Trizero platform is performing very well in vivo and this opens up many other opportunities for line-extension products for MIST-B04.”